KVUE Kenvue Inc.

NYSE www.jnj.com/kenvue/


$ 16.27 $ -0.16 (-0.94 %)    

Tuesday, 18-Nov-2025 14:13:50 EST
QQQ $ 600.62 $ 1.00 (0.17 %)
DIA $ 463.32 $ 1.16 (0.25 %)
SPY $ 663.90 $ 1.80 (0.27 %)
TLT $ 88.96 $ -0.39 (-0.44 %)
GLD $ 375.20 $ 0.36 (0.1 %)
$ 16.24
$ 16.40
$ 16.27 x 2,093
$ 16.28 x 670
$ 16.11 - $ 16.60
$ 13.85 - $ 24.41
54,955,616
na
31.11B
$ 0.90
$ 21.71
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-28-2025 10-Q
2 08-07-2025 06-29-2025 10-Q
3 05-08-2025 03-30-2025 10-Q
4 02-24-2025 12-29-2024 10-K
5 11-07-2024 09-29-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-01-2024 12-31-2023 10-K
9 11-03-2023 10-01-2023 10-Q
10 08-02-2023 07-02-2023 10-Q
11 06-02-2023 04-02-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 two-judges-on-us-appeals-court-reviewing-dismissal-of-private-lawsuits-over-alleged-tylenol-link-to-autism-question-at-a-hearing-whether-expert-testimony-was-properly-excluded

- Reuters

 court-rejects-bid-to-block-kenvues-398-million-shareholder-payout-in-tylenol-safety-dispute

Texas judge rejects bid to block Kenvue's $398 million dividend and declines to restrict Tylenol marketing as the company f...

 barclays-maintains-equal-weight-on-kenvue-raises-price-target-to-18

Barclays analyst Lauren Lieberman maintains Kenvue (NYSE:KVUE) with a Equal-Weight and raises the price target from $17 to $18.

Core News & Articles

https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...

 texas-attorney-general-ken-paxton-files-motion-to-prevent-kenvue-from-paying-out-november-dividend

https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...

 kenvues-487-billion-sale-puts-consumer-staples-etfs-back-in-vogue

The $48.7 billion Kimberly-Clark–Kenvue deal could reshape major consumer staples ETFs like XLP, VDC, and IYK.

 options-corner-kimberly-clarks-implosion-offers-an-unusual-informational-arbitrage-opportunity

Although Kimberly-Clark suffered a huge blow after announcing its Kenvue buyout, KMB stock is flashing a quantitative contraria...

 nvidia-amazon-extend-rally-bitcoin-sinks-to-107000-whats-moving-markets-monday

Wall Street opened the week on a mixed note on Monday.

Core News & Articles

Buffett Sells Stocks

Core News & Articles

https://www.wsj.com/business/deals/activist-investors-in-kenvue-faced-big-losses-kimberly-clark-saved-the-day-df6bb04a

 kenvue-affirms-fy2025-adj-eps-guidance-of-100-105-vs-104-est

Kenvue (NYSE:KVUE) affirms FY2025 Adj EPS guidance from $1.00-$1.05 to $1.00-$1.05 vs $1.04 analyst estimate..

 kimberly-clark-stock-plunges-over-16-kenvue-surges-20-in-monday-pre-market-whats-going-on

Shares of Kimberly-Clark Corporation (NASDAQ: KMB) plunged 16.49% during the pre-market trading session on Monday, after it ann...

 kenvue-q3-adj-eps-028-beats-027-estimate-sales-3764b-miss-3836b-estimate

Kenvue (NYSE:KVUE) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.27 by 5.66 pe...

Core News & Articles

Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Wil...

 hhs-kennedy-on-tylenol-says-not-enough-evidence-to-show-tylenol-definitively-causes-autism-but-some-studies-seem-very-suggestive

https://x.com/US_FDA/status/1983585600214061232

 canaccord-genuity-downgrades-kenvue-to-hold-lowers-price-target-to-15

Canaccord Genuity analyst Susan Anderson downgrades Kenvue (NYSE:KVUE) from Buy to Hold and lowers the price target from $26...

 ken-paxton-alleges-johnson--johnson-misled-mothers-on-tylenol-safety

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION